Committee for Advanced Therapies (CAT)
Draft agenda for the meeting on 06-08 December 2023

Chair: Ilona Reischl; Vice-Chair: Kieran Breen
06 December 2023, 14:00 – 18:30, room 1C
07 December 2023, 09:00 – 18:30, room 1C
08 December 2023, 09:00 – 13:00, room 1C

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
## Table of contents

<table>
<thead>
<tr>
<th>1. Introduction</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1. Welcome and declarations of interest of members, alternates and experts</td>
<td>5</td>
</tr>
<tr>
<td>1.2. Adoption of agenda</td>
<td>5</td>
</tr>
<tr>
<td>1.3. Adoption of the minutes</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. Evaluation of ATMPs</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1. Opinions</td>
<td>5</td>
</tr>
<tr>
<td>2.1.1. Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763</td>
<td>5</td>
</tr>
<tr>
<td>2.2. Oral explanations</td>
<td>5</td>
</tr>
<tr>
<td>2.3. Day 180 list of outstanding issues</td>
<td>5</td>
</tr>
<tr>
<td>2.4. Day 120 list of questions</td>
<td>5</td>
</tr>
<tr>
<td>2.5. Day 80 assessment reports</td>
<td>6</td>
</tr>
<tr>
<td>2.6. Update on ongoing initial applications</td>
<td>6</td>
</tr>
<tr>
<td>2.7. New applications</td>
<td>6</td>
</tr>
<tr>
<td>2.7.1. Beremagene geperpavec - PRIME - Orphan - EMEA/H/C/006330</td>
<td>6</td>
</tr>
<tr>
<td>2.8. Withdrawal of initial marketing authorisation application</td>
<td>6</td>
</tr>
<tr>
<td>2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004</td>
<td>6</td>
</tr>
<tr>
<td>2.10. Companion diagnostics</td>
<td>6</td>
</tr>
<tr>
<td>2.10.1. Initial consultation</td>
<td>6</td>
</tr>
<tr>
<td>2.10.2. Follow-up consultation</td>
<td>6</td>
</tr>
<tr>
<td>2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008</td>
<td>6</td>
</tr>
<tr>
<td>2.11.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0018/G</td>
<td>6</td>
</tr>
<tr>
<td>2.11.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0026/G</td>
<td>7</td>
</tr>
<tr>
<td>2.11.3. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0032</td>
<td>7</td>
</tr>
<tr>
<td>2.11.4. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021</td>
<td>7</td>
</tr>
<tr>
<td>2.11.5. Hemgenix - etranacogene dezaparvovec - Orphan - EMEA/H/C/004827/II/0009/G</td>
<td>8</td>
</tr>
<tr>
<td>2.11.6. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/II/0021</td>
<td>8</td>
</tr>
<tr>
<td>2.11.7. Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/II/0039</td>
<td>8</td>
</tr>
<tr>
<td>2.11.8. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0065</td>
<td>8</td>
</tr>
<tr>
<td>2.12. Extension applications</td>
<td>8</td>
</tr>
<tr>
<td>2.13. Other Post-Authorisation Activities</td>
<td>9</td>
</tr>
</tbody>
</table>
2.13.2. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/014 .................. 9
2.13.3. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/015 .................. 9
2.13.4. Holoclar - ex vivo expanded autologous human corneal epithelial cells containing stem cells - Orphan - EMEA/H/C/002450/R/0058 ................................................................. 9
2.13.5. ROCTAVIAN - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/MEA/003.2 .......... 9
2.13.6. Tecartus - brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/ANX/011.1 ............. 10
2.13.7. Upstaza – eladocagene exuparvovec - EMEA/H/C/005352/S/0017 ................................. 10
2.14. GMP and GCP inspections requests .............................................................................. 10

3. Certification of ATMPs

3.1. Opinion .................................................................................................................. 10
3.2. Day 60 Evaluation Reports .................................................................................. 10
3.3. New Applications ............................................................................................... 10

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator ............................................. 11
4.1.1. Allogeneic expanded natural killer cells............................................................ 11
4.1.2. Autologous tissue generated in the human body (in vivo) through the foreign body reaction .......................................................... 11
4.1.3. Dendritic cells activated by lysate of circulating tumour cells ......................... 11
4.1.4. Autologous T Lymphocytes engineered with nanoparticles with curcumin encapsulated .... 11
4.2. Day 30 ATMP scientific recommendation .......................................................... 11
4.3. Day 60 revised scientific recommendation (following list of questions) ............... 12
4.3.1. Allogeneic peripheral blood-derived HSPC, Treg cells and Tcon cells ............... 12
4.4. Finalisation of procedure ..................................................................................... 12
4.4.1. Live, freeze-dried, genetically modified Lactococcus lactis strain, engineered to secrete human interleukin-10 (hIL-10) and a deamidated, human leukocyte antigen (HLA)-DQ2 restricted, 33-mer alpha-gliadin peptide (dDQ2) .............................................................. 12
4.4.2. Autologous lymphocytes enriched in activated natural killer cells ................. 12
4.4.3. Umbilical cord blood leukocyte concentrate containing cord blood stem cells ...... 12
4.4.4. Umbilical cord blood leukocyte concentrate containing cord blood stem cells ...... 12
4.4.5. DNA plasmid expressing short hairpin RNA (shRNA) against lytic origin of DNA replication of Epstein Barr Virus (EBV) messenger RNA (mRNA) ................................................................. 13
4.4.6. DNA plasmid expressing short hairpin RNA (shRNA) against BCL2 anti-apoptotic messenger RNA (mRNA) ................................................................. 13
4.5. Follow-up and guidance ...................................................................................... 13

5. Scientific Advice

5.1. New requests - appointment of CAT Rapporteurs ................................................. 13
5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers .......... 13
5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs ................................ 13
5.3. Finalisation of D70 procedures – feedback from the discussion meeting .............. 13
5.4. Final Advice Letters for procedures finalised the previous month ...................... 14
6. **Pre-Authorisation Activities**

6.1. Paediatric investigation plans

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

7. **Organisational, regulatory and methodological matters**

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

7.1.2. Mandates for the current joint CHMP-CAT memberships

7.1.3. Vote by proxy

7.1.4. Onboarding Programme for CAT members and alternates

7.1.5. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, 25-27 October 2023 Madrid (Spain)

7.1.6. CAT Strategic Review & Learning meeting (SRLM) under the Belgian presidency

7.2. Coordination with EMA Scientific Committees

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Reflection paper on the use of real-world data to generate real-world evidence in non-interventional studies

7.4. Cooperation with the EU regulatory network

7.4.1. Feedback from EDQM

7.5. Cooperation with international regulators

7.5.1. ICH Cell and Gene Therapy Discussion Group

7.6. CAT work plan

7.6.1. Update on real-world evidence (RWE) studies to support EMA scientific committees

7.6.2. CAT work plan for 2024

7.7. Planning and reporting

7.8. Others

7.8.1. Artificial intelligence for neoantigen-based personalized treatments against cancer

8. **Any other business**

9. **Explanatory notes**
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 06-08 December 2023. See December 2023 CAT minutes (to be published post January 2024 CAT meeting).

1.2. **Adoption of agenda**

CAT agenda for 06-08 December 2023 meeting

1.3. **Adoption of the minutes**

CAT minutes for 28-01 November 2023 meeting

2. **Evaluation of ATMPs**

2.1. **Opinions**

2.1.1. **Exagamglogene autotemcel - PRIME - Orphan - EMEA/H/C/005763**

Vertex Pharmaceuticals (Ireland) Limited; Treatment of transfusion-dependent β-thalassemia and sickle cell disease

Scope: Opinion

**Action:** for adoption


2.2. **Oral explanations**

No items

2.3. **Day 180 list of outstanding issues**

No items

2.4. **Day 120 list of questions**

No items
2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.7.1. Beremagene geperpavec - PRIME - Orphan - EMEA/H/C/006330

Krystal Biotech Netherlands B.V.; Treatment of patients from birth with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

Scope: Timetable for assessment

Action: for adoption

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. Companion diagnostics

2.10.1. Initial consultation

No items

2.10.2. Follow-up consultation

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0018/G

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality, opinion
**Action:** for adoption
Request for supplementary information adopted on 15.06.2023.

### 2.11.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0026/G

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality, opinion
**Action:** for adoption
Request for supplementary information adopted on 08.09.2023.

### 2.11.3. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0032

Bristol-Myers Squibb Pharma EEIG
Rapporteur: Concetta Quintarelli
Scope: Quality, request for supplementary information
**Action:** for adoption

### 2.11.4. CARVYKTI - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/II/0021

Janssen-Cilag International NV
Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays
Scope: Indication, request for supplementary information

Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 1 prior therapy, including an IMiD (Immunomodulatory imide drugs) and a PI (proteasome inhibitors), have demonstrated disease progression on or after the last therapy and are refractory to lenalidomide for CARVYKTI, based on interim results from study MMY3002 listed as a specific obligation (SOB/006) in the Annex II. This is an ongoing, Phase 3, randomised, open-label, multicentre study to determine whether treatment with cilt-cel provides an efficacy benefit compared to standard therapy in participants with relapsed and lenalidomide-refractory multiple myeloma. As a consequence, sections 4.1, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the product information. As part of the application the MAH is requesting a 1-year extension of the market protection.

**Action:** for adoption
Request for supplementary information adopted on 08.09.2023.

2.11.5.  **Hemgenix - etranacogene dezaparvovec - Orphan - EMEA/H/C/004827/II/0009/G**

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: Quality, opinion

**Action:** for adoption


2.11.6.  **Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/II/0021**

Orchard Therapeutics (Netherlands) B.V.

Rapporteur: Emmely de Vries

Scope: Quality, opinion

**Action:** for adoption

2.11.7.  **Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/II/0039**

Fondazione Telethon ETS

Rapporteur: Sol Ruiz

Scope: Quality, request for supplementary information

**Action:** for adoption

2.11.8.  **Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0065**

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical, opinion

Update of section 4.8 of the SmPC in order to add Infusion Related Reactions to the list of adverse drug reactions (ADRs) with frequency Common, based on a cumulative review of the MAH safety database, clinical trials and postmarketing data. The Package Leaflet is updated accordingly.

**Action:** for adoption

2.12.  **Extension applications**

No items
2.13. **Other Post-Authorisation Activities**

2.13.1. **Breyanzi** - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/016

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality

**Action:** for adoption

2.13.2. **CARVYKTI** - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/014

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

**Action:** for adoption

2.13.3. **CARVYKTI** - ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/REC/015

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

**Action:** for adoption

2.13.4. **Holoclar** - ex vivo expanded autologous human corneal epithelial cells containing stem cells - Orphan - EMEA/H/C/002450/R/0058

Holostem Terapie Avanzate s.r.l.

Rapporteur: Egbert Flory, Co-Rapporteur: Concetta Quintarelli, PRAC Rapporteur: Rhea Fitzgerald

Scope: 1 year Renewal of Marketing Authorisation

**Action:** for adoption

Request for supplementary information adopted on 06.10.2023.

2.13.5. **ROCTAVIAN** - valoctocogene roxaparvovec - Orphan - EMEA/H/C/005830/MEA/003.2

BioMarin International Limited

Rapporteur: Violaine Closson Carella

Scope: Pharmacovigilance, adoption of conclusions
MAH response to MEA 003.1 as adopted in July 2023: Impact of ROCTAVIAN on fertility, general toxicity, teratology and germline transmission in females of childbearing potential.

**Action:** for adoption

### 2.13.6. Tecartus - brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/ANX/011.1

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Clinical & Pharmacovigilance, request of supplementary information


**Action:** for adoption

### 2.13.7. Upstaza – eladocagene exuparvovec - EMEA/H/C/005352/S/0017

PTC Therapeutics International Limited

Rapporteur: Maura O’Donovan, Co-Rapporteur: Maria Luttgen

Scope: Annual reassessment, request for supplementary information

**Action:** for adoption

### 2.14. GMP and GCP inspections requests

No items

### 3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

#### 3.1. Opinion

No items

#### 3.2. Day 60 Evaluation Reports

No items

#### 3.3. New Applications

No items
4. **Scientific Recommendation on Classification of ATMPs**


Timetable:
- Start of the procedure: 18.12.2023
- EMA Coordinator’s draft report: 03.01.2024
- CAT Coordinator’s comments: 11.01.2024
- Revised scientific recommendation: 12.01.2024
- CAT’s discussion of scientific recommendation: 19.01.2024

4.1. **New requests – Appointment of CAT Coordinator**

4.1.1. **Allogeneic expanded natural killer cells**

For the treatment of acute myeloid leukaemia

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

4.1.2. **Autologous tissue generated in the human body (in vivo) through the foreign body reaction**

For tissue augmentation

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

4.1.3. **Dendritic cells activated by lysate of circulating tumour cells**

For the treatment of solid tumours in metastatic stage

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

4.1.4. **Autologous T Lymphocytes engineered with nanoparticles with curcumin encapsulated**

For the treatment of melanoma

Scope: Appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

4.2. **Day 30 ATMP scientific recommendation**

No items
4.3. **Day 60 revised scientific recommendation (following list of questions)**

4.3.1. **Allogeneic peripheral blood-derived HSPC, Treg cells and Tcon cells**

Prevention of moderate to severe chronic graft-vs.-host disease and/or death in patients with acute leukaemias and in patients with myelodysplastic syndrome (MDS) undergoing HLA-matched allogeneic hematopoietic stem cell transplant (alloHCT)

Scope: ATMP scientific recommendation

**Action:** for adoption

4.4. **Finalisation of procedure**

4.4.1. **Live, freeze-dried, genetically modified Lactococcus lactis strain, engineered to secrete human interleukin-10 (hIL-10) and a deamidated, human leukocyte antigen (HLA)-DQ2 restricted, 33-mer alpha-gliadin peptide (dDQ2)**

Treatment of celiac disease

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.4.2. **Autologous lymphocytes enriched in activated natural killer cells**

Cancer

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.4.3. **Umbilical cord blood leukocyte concentrate containing cord blood stem cells**

Hypoxic-ischaemic encephalopathy

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.4.4. **Umbilical cord blood leukocyte concentrate containing cord blood stem cells**

Cerebral palsy

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption
4.4.5. DNA plasmid expressing short hairpin RNA (shRNA) against lytic origin of DNA replication of Epstein Barr Virus (EBV) messenger RNA (mRNA)

Treatment of EBV infected patients

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.4.6. DNA plasmid expressing short hairpin RNA (shRNA) against BCL2 anti-apoptotic messenger RNA (mRNA)

Treatment of cancer patients

Scope: European Commission raised no comments. ATMP scientific recommendation

**Action:** for adoption

4.5. **Follow-up and guidance**

No items

5. **Scientific Advice**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. **New requests - appointment of CAT Rapporteurs**

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:
- Start of procedure at SAWP: 27-30.11.2023
- Appointment of CAT Peer Reviewers: 06-08.12.2023
- SAWP first reports: 02.01.2024
- CAT Peer Reviewer comments (NC/C): 05.01.2024
- CAT Peer Reviewer comments (Q): 10.01.2024
- Discussion at SAWP: 08-11.01.2024
- Discussion at CAT and feedback to SAWP: 17-19.01.2024

5.2. **Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs**

5.3. **Finalisation of D70 procedures – feedback from the discussion meeting**

No items
5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment
Procedure start: 27-30.11.2023
SAWP recommendation: 11.01.2024
CAT recommendation: 19.01.2024
CHMP adoption of report and final recommendation: 25.01.2024

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information
7.1.2. Mandates for the current joint CHMP-CAT memberships

Scope: Mandates for the current joint CHMP-CAT memberships will expire on 17.12.2023

Action: for information

7.1.3. Vote by proxy

Action: for information

7.1.4. Onboarding Programme for CAT members and alternates

Scope: Revised Onboarding Programme
CAT: Ilona Reischl

Action: for adoption

7.1.5. CAT Strategic Review & Learning meeting (SRLM) under the Spanish presidency, 25-27 October 2023 Madrid (Spain)

CAT: Sol Ruiz, Marcos Timon
Scope: Presentations from the SRLM

Action: for information

7.1.6. CAT Strategic Review & Learning meeting (SRLM) under the Belgian presidency

CAT: Claire Beuneu
Scope: Date for the upcoming SRLM: 15-17 May 2024

Action: for information

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Reflection paper on the use of real-world data to generate real-world evidence in non-interventional studies

Presenter: Olaf Klungel
Scope: Presentation of the methodology working group (MWP) draft Reflection Paper on real-world evidence

Action: for information
7.4. **Cooperation with the EU regulatory network**

7.4.1. **Feedback from EDQM**

CAT: Catherine Milne

Scope: Planned consultation of EMA and NCAs to explore a certification system for rapid microbial methods

*Action*: for information

7.5. **Cooperation with international regulators**

7.5.1. **ICH Cell and Gene Therapy Discussion Group**

CAT: Jan Müller-Berghaus, Niamh Curran

Scope: To provide an overview of the proposed ICH Cell and Gene Therapy Discussion Group’s workplan and proposed deliverables

*Action*: for information

7.6. **CAT work plan**

7.6.1. **Update on real-world evidence (RWE) studies to support EMA scientific committees**

Scope: To share with the committee the list of new data partners planned to be onboarded in DARWIN EU, the progress of DARWIN EU, house studies and funded studies, and share/discuss possible real-world data (RWD) studies proposals for the future

*Action*: for information

7.6.2. **CAT work plan for 2024**

CAT: Ilona Reischl

Scope: Draft CAT work plan for 2024

*Action*: for discussion

7.7. **Planning and reporting**

No items
7.8. **Others**

7.8.1. **Artificial intelligence for neoantigen-based personalized treatments against cancer**

Scope: Lecture

**Action:** for information

8. **Any other business**

No items

Date of next CAT meeting:

17-19 January 2024
9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:
List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA’s regulatory activities

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures) (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.
Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Companion diagnostics (section 2.10)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation
is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

**ITF Briefing meeting in the field of ATMPs**

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

**Priority Medicines (PRIME)**

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

**Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

**Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)